


Amendments to the Claims

1. (Currently amended) A compound structurally represented by Formula I



(I)

or a pharmaceutically acceptable salts thereof wherein:

G¹ is -CH₂-, or -CH₂-CH₂-,

G² is -CH₂-, or -C(O)-,

or G¹ and G² taken together combine to form -CH=CH- or -CH₂-CH=CH-,

Y is

-OCH₂CH₂N-piperidinyl, or

-OCH₂CH₂CH₂N-piperidinyl,

-OCH₂CH₂N-pyrrolidinyl,

-OCH₂CH₂CH₂N-pyrrolidinyl,


X is H, -COR³, -CH₂R⁴, or -SO₂R⁵,

R³ is

-(C₁-C₈) alkyl, optionally substituted with 1 to 3 halogens,

-(C₃-C₈) cycloalkyl, optionally substituted with 1 to 3 halogens,

-O(C₁-C₈) alkyl, optionally substituted with 1 to 3 halogens,



, wherein R⁶ is -(C₁-C₆) alkyl, or -COO-(C₁-C₆) alkyl,

-Furanyl,

-Thienyl,

-NH-phenyl,


-NH-(C₁-C₄)alkyl-phenyl,

-NH-(C₁-C₈) alkyl, optionally substituted with 1 to 4 halogens,

-NH-(C₃-C₈) cycloalkyl, optionally substituted once or twice with halogens,
 -CH₂-pyridinyl,
 -CH₂N (C₁-C₆) alkyl (C₁-C₆) alkyl, or
 -CH₂N-phenyl,

R⁴ is

-(C₁-C₈) alkyl, optionally substituted with 1 to 4 halogens,
 -(C₃-C₈) cycloalkyl,
 -(C₁-C₈) alkyl-NH₂,
 -(C₁-C₄) alkyl-phenyl,
 -CH₂N-phenyl,
 -phenyl-O-(C₁-C₄) alkyl-phenyl,
 -(C₁-C₄) alkyl-O-(C₁-C₄) alkyl-phenyl,
 -CH₂NCO₂-(C₁-C₆) alkyl,
 -Phenyl,
 -Thienyl,
 -Furanyl,
 -Imidazolyl,
 -Naphthyl, or



, wherein R⁶ is -(C₁-C₆) alkyl, or -COO-(C₁-C₆) alkyl,

-biphenyl, and






R⁵ is







-Phenyl,
 -(C₁-C₄) alkyl, or
 -(C₁-C₄) alkyl-phenyl,

provided the compound is not 6-(2-Piperidin-1-yl-ethoxy)-2,3-dihydro-1H-indole.








2. (Currently amended) The compound of claim 1, wherein G¹ is -CH₂- ~~R¹ and R² cyclize to form a 5-membered ring~~, or a pharmaceutically acceptable salt thereof.






3. (Currently amended) The compound of claim 1, wherein G^1 is $-\text{CH}_2-\text{CH}_2-$ ~~R^1 and R^2 cyclize to form a 6-membered ring,~~ or a pharmaceutically acceptable salt thereof.
4. (Currently amended) The compound of claim 2 wherein Y is in the 5 position, or a pharmaceutically acceptable salt thereof.
5. (Currently amended) The compound of claim 3 wherein Y is in the 6 position, or a pharmaceutically acceptable salt thereof.
6. (Cancelled)
7. (Currently amended) The compound of claim 1, selected from the group consisting of:







Example Number	<u>Structure</u>
1	
2	
3	
4	
5	






6	
7	
8	
9	
10	
11	






12	 <chem>CC(C)(C)OC(=O)N1CCc2cc(OCCCN)ccc2C1</chem>
13	 <chem>ClCCCOc1ccc2c(c1)ccncc2</chem>
14	 <chem>CCN1CCc2cc(OCCCN)ccc2C1</chem>
15	 <chem>ClCCCOc1ccc2c(c1)cc(NC3CCCCC3)cc2</chem>
16	 <chem>ClCCCOc1ccc2c(c1)cc(=O)nc2</chem>
17	 <chem>ClCCCOc1ccc2c(c1)cc(CS3=CC=CC3)cc2</chem>






18	
19	
20	
21	
22	
23	
24	






25	
26	
27	
28	
29	







30	
31	
32	
33	
34	
35	




36	
37	
38	
39	
40	

41	 <chem>CCCC1=CC=C2C(=C1)C(=CN2S(=O)(=O)C)OCCCN3CCCCC3</chem>
42	 <chem>CCCC1=CC=C2C(=C1)C(=CN2S(=O)(=O)CCC)OCCCN3CCCCC3</chem>
43	 <chem>CCCC1=CC=C2C(=C1)C(=CN2S(=O)(=O)Cc3ccccc3)OCCCN3CCCCC3</chem>
44	 <chem>CCCC1=CC=C2C(=C1)C(=CN2C(=O)NCCc3ccccc3)OCCCN3CCCCC3</chem>
45	 <chem>CCCC1=CC=C2C(=C1)C(=CN2C(=O)N(C)C)OCCCN3CCCCC3</chem>

46	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)c(c[nH]3)C(=O)Nc4ccccc4</chem>
47	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)c(c[nH]3)C(=O)Nc4ccccc4</chem>
48	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)c(c[nH]3)C(=O)Nc4ccccc4</chem>
49	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)c(c[nH]3)C(=O)Nc4ccccc4</chem>
50	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)c(c[nH]3)C(=O)Nc4ccccc4</chem>

51	 <p>Chiral</p>
52	 <p>Chiral</p>
53	
54	
55	

56	
57	Chiral 
58	
59	Chiral 
60	Chiral 
61	

62	 <chem>C1CCN(CC1)CCCOc2cc(Cl)c(c3c2c(Cl)c(c3)NCCCCc4ccccc4)cc2</chem>
63	 <chem>C1CCN(CC1)CCCOc2cc(Cl)c(c3c2c(Cl)c(c3)NCCNc4ccccc4)cc2</chem>
64	 <chem>C1CCN(CC1)CCCOc2cc3c(c1c2)cc(c3)NCC4CCCCC4</chem>

or a pharmaceutically acceptable salt or solvate thereof.

8. (Previously presented) A pharmaceutical composition which comprises a compound of claims 1 or 7 and a pharmaceutically acceptable carrier.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)